PharmaShots | Incisive News in 3 Shots

Subscribe Now

Amivantamab

Janssen Presents Results of Rybrevant (amivantamab-vmjw) in P-I CHRYSALIS Study for Advanced NSCLC with METex14 Mutations at WCLC

Janssen Presents Results of Rybrevant (amivantamab-vmjw) in P-I CHRYSALIS Study for Advanced NSCLC with METex14 Mutations at WCLC

August 20, 2021

PharmaShots Interview: Janssen's Mark Wildgust along with Two Other Key Speakers Share Insights on Data Presented at ASCO 2021

PharmaShots Interview: Janssen's Mark Wildgust along with Two Other Key Speakers Share Insights on Data Presented at ASCO 2021

July 19, 2021

PharmaShots Interview: Janssen's Kiran Patel Shares Insights on Amivantamab for Metastatic EGFR Exon 20+ NSCLC

PharmaShots Interview: Janssen's Kiran Patel Shares Insights on Amivantamab for Metastatic EGFR Exon 20+ NSCLC

January 13, 2021

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us